Literature DB >> 24287185

Decrease in antibiotic use, an added benefit of PCVs.

Carlos G Grijalva1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24287185      PMCID： PMC4831623          DOI： 10.1016/S1473-3099(13)70356-6

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN： 1473-3099            Impact factor:   25.071


× No keyword cloud information.
  17 in total

Review 1.  Limiting the spread of resistant pneumococci: biological and epidemiologic evidence for the effectiveness of alternative interventions.

Authors:  S J Schrag; B Beall; S F Dowell
Journal:  Clin Microbiol Rev       Date:  2000-10       Impact factor: 26.132

2.  Rethinking replacement and resistance.

Authors:  Matthew R Moore
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

Review 3.  A review of the effect of immunization programs on antimicrobial utilization.

Authors:  Kyle J Wilby; Denise Werry
Journal:  Vaccine       Date:  2012-08-29       Impact factor: 3.641

4.  Prevention of antibiotic-nonsusceptible Streptococcus pneumoniae with conjugate vaccines.

Authors:  Lee M Hampton; Monica M Farley; William Schaffner; Ann Thomas; Arthur Reingold; Lee H Harrison; Ruth Lynfield; Nancy M Bennett; Susan Petit; Kenneth Gershman; Joan Baumbach; Bernard Beall; James Jorgensen; Anita Glennen; Elizabeth R Zell; Matthew Moore
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

5.  Cost-effectiveness of using 2 vs 3 primary doses of 13-valent pneumococcal conjugate vaccine.

Authors:  Charles Stoecker; Lee M Hampton; Ruth Link-Gelles; Mark L Messonnier; Fangjun Zhou; Matthew R Moore
Journal:  Pediatrics       Date:  2013-07-01       Impact factor: 7.124

6.  Effect of introduction of the pneumococcal conjugate vaccine on drug-resistant Streptococcus pneumoniae.

Authors:  Moe H Kyaw; Ruth Lynfield; William Schaffner; Allen S Craig; James Hadler; Arthur Reingold; Ann R Thomas; Lee H Harrison; Nancy M Bennett; Monica M Farley; Richard R Facklam; James H Jorgensen; John Besser; Elizabeth R Zell; Anne Schuchat; Cynthia G Whitney
Journal:  N Engl J Med       Date:  2006-04-06       Impact factor: 91.245

7.  Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.

Authors:  Arto A Palmu; Jukka Jokinen; Dorota Borys; Heta Nieminen; Esa Ruokokoski; Lotta Siira; Taneli Puumalainen; Patricia Lommel; Marjan Hezareh; Marta Moreira; Lode Schuerman; Terhi M Kilpi
Journal:  Lancet       Date:  2012-11-16       Impact factor: 79.321

8.  Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Patrick G Arbogast; Stacey W Martin; Kathryn M Edwards; Marie R Griffin
Journal:  Lancet       Date:  2007-04-07       Impact factor: 79.321

Review 9.  Impact of conjugate pneumococcal vaccines on antibiotic resistance.

Authors:  Ron Dagan; Keith P Klugman
Journal:  Lancet Infect Dis       Date:  2008-12       Impact factor: 25.071

10.  A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection.

Authors:  Keith P Klugman; Shabir A Madhi; Robin E Huebner; Robert Kohberger; Nontombi Mbelle; Nathaniel Pierce
Journal:  N Engl J Med       Date:  2003-10-02       Impact factor: 91.245
View more
  2 in total

1.  A Cation-Binding Surface Protein as a Vaccine Antigen To Prevent Moraxella catarrhalis Otitis Media and Infections in Chronic Obstructive Pulmonary Disease.

Authors:  Timothy F Murphy; Aimee L Brauer; Antoinette Johnson; Gregory E Wilding; Mary Koszelak-Rosenblum; Michael G Malkowski
Journal:  Clin Vaccine Immunol       Date:  2017-09-05

2.  Invasive Pneumococcal Disease in Refugee Children, Germany.

Authors:  Stephanie Perniciaro; Matthias Imöhl; Mark van der Linden
Journal:  Emerg Infect Dis       Date:  2018-10       Impact factor: 6.883
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.